Abstract
Considerable evidence has been provided these last years for the involvement of the GABA-A receptor complex in memory processes. Compounds that enhance the action of GABA, such as benzodiazepines, impair memory processing. On the contrary, compounds that reduce the action of GABA, such as ß-CCM, pentylenetetrazol or picrotoxin, have the opposite action, that is : enhance memory processing. All these actions seem to focus mainly on the acquisition (learning) processes. Depending on the dose, the same compounds also have effects on anxiety and on seizuring. Benzodiazepines are well-known anxiolytic and anticonvulsant agents whereas compounds that reduce the action of GABA have been found to produce anxiogenic and convulsant actions. The GABA-A receptor complex might thus be the location of a possible link between a pathological state (epilepsy) and two normal functions (anxiety and learning). This link is likely to involve common genetic pathways. In the normal subject, these data also emphasize the idea that normal memory processing involves a moderate level of anxiety.
Keywords: gaba receptor complex, pentylenetetrazol, picrotoxin, learning, anxiety, epilepsy
Current Topics in Medicinal Chemistry
Title: GABA-A Receptor Complex and Memory Processes
Volume: 2 Issue: 8
Author(s): Georges Chapouthier and Patrice Venault
Affiliation:
Keywords: gaba receptor complex, pentylenetetrazol, picrotoxin, learning, anxiety, epilepsy
Abstract: Considerable evidence has been provided these last years for the involvement of the GABA-A receptor complex in memory processes. Compounds that enhance the action of GABA, such as benzodiazepines, impair memory processing. On the contrary, compounds that reduce the action of GABA, such as ß-CCM, pentylenetetrazol or picrotoxin, have the opposite action, that is : enhance memory processing. All these actions seem to focus mainly on the acquisition (learning) processes. Depending on the dose, the same compounds also have effects on anxiety and on seizuring. Benzodiazepines are well-known anxiolytic and anticonvulsant agents whereas compounds that reduce the action of GABA have been found to produce anxiogenic and convulsant actions. The GABA-A receptor complex might thus be the location of a possible link between a pathological state (epilepsy) and two normal functions (anxiety and learning). This link is likely to involve common genetic pathways. In the normal subject, these data also emphasize the idea that normal memory processing involves a moderate level of anxiety.
Export Options
About this article
Cite this article as:
Chapouthier Georges and Venault Patrice, GABA-A Receptor Complex and Memory Processes, Current Topics in Medicinal Chemistry 2002; 2 (8) . https://dx.doi.org/10.2174/1568026023393552
DOI https://dx.doi.org/10.2174/1568026023393552 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanotechnological Advances in the Treatment of Epilepsy
CNS & Neurological Disorders - Drug Targets The Current WHO Classification of Tumours of the Central Nervous System: Histopathology and Additional Diagnostic Methods
Current Medical Imaging Changes in Bone Turnover, Bone Mineral and Fracture Risk Induced by Drugs Used to Treat Epilepsy
Current Drug Safety Drug Transporters in Chemotherapy Induced Peripheral Neurotoxicity:Current Knowledge and Clinical Implications
Current Medicinal Chemistry 3D-QSAR and Docking Simulation Studies of Some Benzopyrone Derivatives as Inhibitors for Breast Cancer Stem Cell Growth via PGlycoprotein Mediated Efflux
Current Bioinformatics Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson’s Disease
Current Aging Science Population Pharmacokinetics of Levetiracetam: A Systematic Review
Current Reviews in Clinical and Experimental Pharmacology Design, Synthesis and Pharmacological Evaluation of N3 Aryl/ Heteroaryl Substituted 2-((Benzyloxy and Phenylthio) Methyl) 6,7- dimethoxyquinazolin-4(3H)-ones as Potential Anticonvulsant Agents
Medicinal Chemistry Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Self-Regulatory Control and Habit Learning in the Development of Eating Disorders
Current Psychiatry Reviews Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions
Current Pharmaceutical Design EEG Upper/Low Alpha Frequency Power Ratio and the Impulsive Disorders Network in Subjects with Mild Cognitive Impairment.
Current Alzheimer Research New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets The Intestinal Absorption Mechanism of Gabapentin Makes it Appropriate for Gastroretentive Delivery
Current Clinical Pharmacology Pharmacology of Recombinant Low-Voltage Activated Calcium Channels
Current Drug Targets - CNS & Neurological Disorders In Silico Approaches Towards the Understanding of the Structure- Function Relationships in Metabotropic Glutamate Receptors (mGluRs) and other Family C GPRCs
Current Pharmaceutical Design ABC Transporters in Extrahepatic Tissues: Pharmacological Regulation in Heart and Intestine
Current Medicinal Chemistry